Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. brain disorder
Show results for
Products
Services
Software
Applications

Companies

News
Articles
Downloads
Videos

Refine by
Date

  • Older

Brain Disorder Articles & Analysis

31 news found

Elucid Appoints Dr. Michael Lesh to Board of Directors

Elucid Appoints Dr. Michael Lesh to Board of Directors

He is also executive chairman of Cordance Medical, a company revolutionizing treatment of cancer, Alzheimer’s disease, and other brain disorders using non-invasive transcranial focused ultrasound to temporarily open the blood-brain-barrier. ...

ByElucid


Neuropathix, Inc. Highlights Revenue Related to its Grant Award with NIH-NINDS

Neuropathix, Inc. Highlights Revenue Related to its Grant Award with NIH-NINDS

Research reported in this publication was supported by the National Institute Of Neurological Disorders And Stroke (NINDS) of the National Institutes of Health (NIH) under Award Number R42NS120548. ...

ByNeuropathix, Inc.


UT Health San Antonio offers summer program for people with aphasia

UT Health San Antonio offers summer program for people with aphasia

” Although stroke is the most common cause, aphasia can also occur due to traumatic brain injury or neurodegenerative disorders. There are two main types of aphasia. ...

ByBioMedSA


Neuropathix, Inc. Highlights Positive Preclinical Study Results on Lead Drug Candidate KLS-13019

Neuropathix, Inc. Highlights Positive Preclinical Study Results on Lead Drug Candidate KLS-13019

Even more noteworthy, results from the studies revealed that KLS-13019 did not bind to opioid receptors in the brain, meaning it holds a very low risk for chemical dependency. “Following our recent grant award from the National Institute of Health – National Institute of Neurological Disorders and Stroke (NIH-NINDS), under the HEAL initiative, these ...

ByNeuropathix, Inc.


Neuropathix, Inc. CEO Issues New Letter to Shareholders; Updates Market on Milestones in Research and Funding

Neuropathix, Inc. CEO Issues New Letter to Shareholders; Updates Market on Milestones in Research and Funding

-Shareholder-Letter-220406.pdf Research reported in this publication was supported by the National Institute Of Neurological Disorders And Stroke (NINDS) of the National Institutes of Health (NIH) under Award Number R42NS120548. ...

ByNeuropathix, Inc.


Inscopix Expands Strategic Partnership with GRINTECH to Become Exclusive Global Supplier of GRIN lenses

Inscopix Expands Strategic Partnership with GRINTECH to Become Exclusive Global Supplier of GRIN lenses

Inscopix, Inc., a neuroscience company helping decode the brain for tomorrow’s treatments, announced that it is expanding its strategic supplier partnership with leading gradient index (GRIN) lens manufacturer GRINTECH GmbH to be the sole exclusive seller of GRIN lenses for neuroscience research applications. ...

ByInscopix Inc.


Inscopix Expands Applications with Blood Flow Imaging to Study Relationship between Brain Activity and Vascular Dynamics

Inscopix Expands Applications with Blood Flow Imaging to Study Relationship between Brain Activity and Vascular Dynamics

With the Inscopix platform now able to perform blood flow and neuronal imaging studies simultaneously within deep brain regions over months, researchers will have unprecedented access to study the underpinnings of neurodegenerative and neurological disorders. ...

ByInscopix Inc.


New National Survey of People Living with Bipolar I Disorder Provides Insights Into Disease-Related Challenges and the Treatment Journey

New National Survey of People Living with Bipolar I Disorder Provides Insights Into Disease-Related Challenges and the Treatment Journey

For complete survey methodology, including weighting variables and subgroup sample sizes, or for any additional questions regarding the survey, please send requests to mediainfo@alkermes.com. About Bipolar I Disorder Bipolar disorder is a brain disorder that is marked by extreme changes in a person's mood, energy and ability ...

ByAlkermes


Neeuro (Singapore) and epihunter (Belgium) partner to create new and innovative digital solutions for people with brain disorders

Neeuro (Singapore) and epihunter (Belgium) partner to create new and innovative digital solutions for people with brain disorders

The company built a digital platform that applies real-time AI to wearable electroencephalograms (EEG) to externalize brain state changes that provide real-time digital interventions to reduce the daily life impact of a brain disorder and to generate real-world data for better treatments. ...

ByEpihunter NV


Neuropathix, Inc. Chooses Purisys for Process Optimization and Scale Up of Its Lead Drug Candidate KLS-13019

Neuropathix, Inc. Chooses Purisys for Process Optimization and Scale Up of Its Lead Drug Candidate KLS-13019

About KLS-13019 KLS-13019 is Neuropathix patented lead clinical target for the potential treatment of a range of neurotoxic, neurodegenerative and neuropathic pain disorders, beginning with CIPN. KLS-13019 is a monotherapeutic non-opioid cannabinoid derivative that has been shown to prevent and reverse neuropathic pain in pre-clinical animal studies. ...

ByNeuropathix, Inc.


Neuropathix, Inc. Wholly Owned Subsidiary Kannalife Sciences, Inc. Awarded $2.97 Million Phase 2 Study Grant from National Institute of Neurological Disorders and Stroke (NINDS)

Neuropathix, Inc. Wholly Owned Subsidiary Kannalife Sciences, Inc. Awarded $2.97 Million Phase 2 Study Grant from National Institute of Neurological Disorders and Stroke (NINDS)

(“Neuropathix” or the “Company”) (OTCQB:NPTX), a socially responsible pain management life sciences company, today announces that its wholly owned subsidiary, Kannalife Sciences, Inc. has received a notice of award from the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH) for a $2.97 million Phase 2 ...

ByNeuropathix, Inc.


Neuropathix, Inc. Forms Dermique Incorporated its New Wholly Owned Subsidiary for the Ownership and Commercialization of the Company’s Over-The-Counter Cosmeceutical Assets

Neuropathix, Inc. Forms Dermique Incorporated its New Wholly Owned Subsidiary for the Ownership and Commercialization of the Company’s Over-The-Counter Cosmeceutical Assets

We now move into the commercial phase of development for LEA™ and, as such, we have now formed Dermique to capitalize on LEA™ as well as the underlying brands we intend to bring to the market for a variety of disorders and skin problems. Our preclinical studies have demonstrated, alongside certain isolated test subjects, that LEA™ is simply better than CBD for ...

ByNeuropathix, Inc.


Faster & Better EEG Tests with Zeto Health Technology Podcast with Aswin Gunasekar, CEO & Founder, Zeto

Faster & Better EEG Tests with Zeto Health Technology Podcast with Aswin Gunasekar, CEO & Founder, Zeto

For the August installment of the Healthtech Leader of the Month series, we interviewed Aswin Gunasekar, founder and CEO of Zeto. Zeto is a device-driven platform for acquiring, accessing, and interpreting electroencephalograms (EEGs). An EEG is a test used to evaluate electrical activity in the ...

ByZeto, Inc.


Neuropathix, Inc. Announces Publication of PCT Patent Application for the Treatment of Radiation Dermatitis and Other Skin Disorders

Neuropathix, Inc. Announces Publication of PCT Patent Application for the Treatment of Radiation Dermatitis and Other Skin Disorders

WO/2021/097351 “Functionalized 1,3-Benzene Diols and Their Method of Use for the Treatment of Radiation Dermatitis and Other Skin Disorders.” One of the compounds disclosed as part of this PCT Patent is the Company’s proprietary ingredient LEA™. ...

ByNeuropathix, Inc.


Wireless EEG for Fast Prep and Easy Use: Q&A with Aswin Gunasekar, CEO of Zeto

Wireless EEG for Fast Prep and Easy Use: Q&A with Aswin Gunasekar, CEO of Zeto

Electroencephalography (EEG) devices are incredibly helpful in diagnosing and monitoring certain brain disorders, such as epilepsy and strokes. However, they are not particularly user-friendly or convenient, with specialized technicians performing time consuming procedures, such as skin preparation, to get patients ready to undergo the procedure. ...

ByZeto, Inc.


New study tests “first-of-its-kind” EEG device

New study tests “first-of-its-kind” EEG device

A press release states that EEG (electroencephalogram) tests are conducted to detect problems in the brain that may be associated with certain brain disorders such as seizures, tumors or strokes. ...

ByZeto, Inc.


Methodist University Hospital Is First In The World To Participate In Groundbreaking EEG Study For Inpatients That Improves Brain Monitoring During the COVID-19 Crisis

Methodist University Hospital Is First In The World To Participate In Groundbreaking EEG Study For Inpatients That Improves Brain Monitoring During the COVID-19 Crisis

EEG tests are conducted to detect problems in the brain that may be associated with certain brain disorders such as seizures, tumors or strokes. ...

ByZeto, Inc.


Kannalife, Inc. Bolsters IP Portfolio with Multiple Patents Issued in 12 Key European Territories

Kannalife, Inc. Bolsters IP Portfolio with Multiple Patents Issued in 12 Key European Territories

“These key pharmacological benefits open the door to a host of other peripheral and central nervous system diseases and disorders as well.” KLS-13019 leads Kannalife’s intellectual property portfolio of novel monotherapeutic molecules (“KLS Family”), which have been proven capable of acting as neuroprotective agents and have the potential to treat a ...

ByNeuropathix, Inc.


Kannalife, Inc. Announces Results from Comparative UVB-Radiation Study on Atopidine Versus CBD

Kannalife, Inc. Announces Results from Comparative UVB-Radiation Study on Atopidine Versus CBD

Kannalife, Inc. is a biopharmaceutical medchem company focused on the development of proprietary and patented novel, monotherapeutic molecules for patients suffering from unmet medical needs of neurodegenerative disorders – including chemotherapy-induced peripheral neuropathy (CIPN), a chronic neuropathy caused by toxic chemotherapeutic agents; hepatic encephalopathy (HE), ...

ByNeuropathix, Inc.


Kannalife, Inc. Announces Results from Comparative UVB-Radiation Study on Atopidine Versus CBD

Kannalife, Inc. Announces Results from Comparative UVB-Radiation Study on Atopidine Versus CBD

Kannalife, Inc. is a biopharmaceutical medchem company focused on the development of proprietary and patented novel, monotherapeutic molecules for patients suffering from unmet medical needs of neurodegenerative disorders – including chemotherapy-induced peripheral neuropathy (CIPN), a chronic neuropathy caused by toxic chemotherapeutic agents; hepatic encephalopathy (HE), ...

ByNeuropathix, Inc.

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT